Literature DB >> 25613442

Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis.

Sven-Petter Haugvik1, Per Hedenström, Emilie Korsæth, Roberto Valente, Alastair Hayes, Darko Siuka, Patrick Maisonneuve, Ivar Prydz Gladhaug, Björn Lindkvist, Gabriele Capurso.   

Abstract

BACKGROUND AND AIMS: Risk factors for pancreatic neuroendocrine tumors (PNETs) are not well understood. The aim of this systematic review was to assess if diabetes mellitus, smoking, alcohol use, and family history of cancer are risk factors for PNETs.
METHODS: MEDLINE and abstracts from the European and North American Neuroendocrine Tumor Societies (ENETS and NANETS) were searched for studies published until October 2013. Eligible studies were selected according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
RESULTS: Five studies evaluating 4 individual populations were included (study accrual period 2000-2011) into the meta-analysis, involving 827 cases (range 160-309 per study) and 2,407 controls (range 233-924 per study). All studies had a case-control design and described regional series. The pooled adjusted odds ratio was 2.74 (95% CI: 1.63-4.62; p < 0.01; I(2) = 60.4%) for history of diabetes, 1.21 (95% CI: 0.92-1.58; p = 0.18; I(2) = 45.8%) for ever smoking, 1.37 (95% CI: 0.99-1.91; p = 0.06; I(2) = 0.0%) for heavy smoking, 1.09 (95% CI: 0.64-1.85; p = 0.75; I(2) = 85.2%) for ever alcohol use, 2.72 (95% CI: 1.25-5.91; p = 0.01; I(2) = 57.8%) for heavy alcohol use, and 2.16 (95% CI: 1.64-2.85; p < 0.01; I(2) = 0.0%) for first-degree family history of cancer.
CONCLUSIONS: Diabetes mellitus and first-degree family history of cancer are associated with an increased risk of sporadic PNET. There was also a trend for diagnosis of sporadic PNET associated with heavy smoking. Alcohol use may be a risk factor for PNET, but there was considerable heterogeneity in the meta-analysis. These results suggest the need for a larger, homogeneous, international study for the clarification of risk factors for the occurrence of PNET.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25613442     DOI: 10.1159/000375164

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  21 in total

Review 1.  The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.

Authors:  Shilpa Thakur; Brianna Daley; Joanna Klubo-Gwiezdzinska
Journal:  J Mol Endocrinol       Date:  2019-08       Impact factor: 5.098

2.  Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.

Authors:  Sahityasri Thapi; Kiwoon Baeg; Michelle K Kim; Emily J Gallagher
Journal:  Pancreas       Date:  2021-10-01       Impact factor: 3.243

3.  Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.

Authors:  T Feola; G Puliani; F Sesti; R Modica; R Centello; R Minotta; G Cannavale; S Di Meglio; V Di Vito; R Lauretta; M Appetecchia; A Colao; A Lenzi; A M Isidori; A Faggiano; E Giannetta
Journal:  J Endocrinol Invest       Date:  2022-01-18       Impact factor: 4.256

4.  Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.

Authors:  Rachel L Dittmar; Suyu Liu; Mei Chee Tai; Kimal Rajapakshe; Ying Huang; Gary Longton; Christine DeCapite; Mark W Hurd; Pamela L Paris; Kimberly S Kirkwood; Cristian Coarfa; Anirban Maitra; Randall E Brand; Ann M Killary; Subrata Sen
Journal:  Cancer Prev Res (Phila)       Date:  2021-04-23

5.  Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors.

Authors:  Daniele Campa; Gabriele Capurso; Manuela Pastore; Renata Talar-Wojnarowska; Anna Caterina Milanetto; Luca Landoni; Evaristo Maiello; Rita T Lawlor; Ewa Malecka-Panas; Niccola Funel; Maria Gazouli; Antonio De Bonis; Harald Klüter; Maria Rinzivillo; Gianfranco Delle Fave; Thilo Hackert; Stefano Landi; Peter Bugert; Franco Bambi; Livia Archibugi; Aldo Scarpa; Verena Katzke; Christos Dervenis; Valbona Liço; Sara Furlanello; Oliver Strobel; Francesca Tavano; Daniela Basso; Rudolf Kaaks; Claudio Pasquali; Manuel Gentiluomo; Cosmeri Rizzato; Federico Canzian
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

6.  Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis.

Authors:  Yi-Wei Dong; Yan-Qiang Shi; Li-Wen He; Xi-Yu Cui; Pei-Zhu Su
Journal:  Oncotarget       Date:  2017-05-26

7.  Characterization of the salivary microbiome in patients with pancreatic cancer.

Authors:  Pedro J Torres; Erin M Fletcher; Sean M Gibbons; Michael Bouvet; Kelly S Doran; Scott T Kelley
Journal:  PeerJ       Date:  2015-11-05       Impact factor: 2.984

8.  Effect of glycemic control on the risk of pancreatic cancer: A nationwide cohort study.

Authors:  Kian-Ching Er; Chen-Yang Hsu; Yi-Kung Lee; Ming-Yuan Huang; Yung-Cheng Su
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 9.  Epidemiology of pancreatic cancer.

Authors:  Milena Ilic; Irena Ilic
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

10.  Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study.

Authors:  Yael N Kusne; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Kyle E Coppola; Kelley A Rone; Curtiss B Cook; Nina J Karlin
Journal:  Future Sci OA       Date:  2021-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.